Outcome of R-CHOP or CHOP Regimen for Germinal Center and Nongerminal Center Subtypes of Diffuse Large B-Cell Lymphoma of Chinese Patients
Diffuse large B-cell lymphoma (DLBCL) can be molecularly subtyped as either germinal center B-cell (GCB) or non-GCB. The role of rituximab(R) in these two groups remains unclear. We studied 204 patients with de novo DLBCL (107 treated with first-line CHOP; 97 treated with first-line R-CHOP), patient...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1100/2012/897178 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849307863800872960 |
|---|---|
| author | Ying Huang Sheng Ye Yabing Cao Zhiming Li Jiajia Huang He Huang Muyan Cai Rongzhen Luo Tongyu Lin |
| author_facet | Ying Huang Sheng Ye Yabing Cao Zhiming Li Jiajia Huang He Huang Muyan Cai Rongzhen Luo Tongyu Lin |
| author_sort | Ying Huang |
| collection | DOAJ |
| description | Diffuse large B-cell lymphoma (DLBCL) can be molecularly subtyped as either germinal center B-cell (GCB) or non-GCB. The role of rituximab(R) in these two groups remains unclear. We studied 204 patients with de novo DLBCL (107 treated with first-line CHOP; 97 treated with first-line R-CHOP), patients being stratified into GCB and non-GCB on the basis of BCL-6, CD10, and MUM1 protein expression. The relationships between clinical characteristics, survival data, and immunophenotype (IHC) were studied. The 5-year overall survival (OS) in the CHOP and R-CHOP groups was 50.4% and 66.6% (P=0.031), respectively. GCB patients had a better 5-year OS than non-GCB patients whether treated with CHOP or not (65.0% versus 40.9%; P=0.011). In contrast, there is no difference in the 5-year OS for the GCB and non-GCB with R-CHOP (76.5% versus 61.3%; P=0.141). In non-GCB subtype, additional rituximab improved survival better than CHOP (61.3% versus 40.9%; P=0.0303). These results indicated that addition of rituximab to standard chemotherapy eliminates the prognostic value of IHC-defined GCB and non-GCB phenotypes in DLBCL by improving the prognostic value of non-GCB subtype of DLBCL. |
| format | Article |
| id | doaj-art-2a74ad2b35914e78b0cbeaa73a717dc2 |
| institution | Kabale University |
| issn | 1537-744X |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Scientific World Journal |
| spelling | doaj-art-2a74ad2b35914e78b0cbeaa73a717dc22025-08-20T03:54:37ZengWileyThe Scientific World Journal1537-744X2012-01-01201210.1100/2012/897178897178Outcome of R-CHOP or CHOP Regimen for Germinal Center and Nongerminal Center Subtypes of Diffuse Large B-Cell Lymphoma of Chinese PatientsYing Huang0Sheng Ye1Yabing Cao2Zhiming Li3Jiajia Huang4He Huang5Muyan Cai6Rongzhen Luo7Tongyu Lin8State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, ChinaDepartment of Medical Oncology, The First affiliated Hospital of Sun Yat-sen University, 58 zhongshan Road, Guangzhou 510080, ChinaState Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, ChinaState Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, ChinaState Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, ChinaState Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, ChinaState Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, ChinaState Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, ChinaState Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, ChinaDiffuse large B-cell lymphoma (DLBCL) can be molecularly subtyped as either germinal center B-cell (GCB) or non-GCB. The role of rituximab(R) in these two groups remains unclear. We studied 204 patients with de novo DLBCL (107 treated with first-line CHOP; 97 treated with first-line R-CHOP), patients being stratified into GCB and non-GCB on the basis of BCL-6, CD10, and MUM1 protein expression. The relationships between clinical characteristics, survival data, and immunophenotype (IHC) were studied. The 5-year overall survival (OS) in the CHOP and R-CHOP groups was 50.4% and 66.6% (P=0.031), respectively. GCB patients had a better 5-year OS than non-GCB patients whether treated with CHOP or not (65.0% versus 40.9%; P=0.011). In contrast, there is no difference in the 5-year OS for the GCB and non-GCB with R-CHOP (76.5% versus 61.3%; P=0.141). In non-GCB subtype, additional rituximab improved survival better than CHOP (61.3% versus 40.9%; P=0.0303). These results indicated that addition of rituximab to standard chemotherapy eliminates the prognostic value of IHC-defined GCB and non-GCB phenotypes in DLBCL by improving the prognostic value of non-GCB subtype of DLBCL.http://dx.doi.org/10.1100/2012/897178 |
| spellingShingle | Ying Huang Sheng Ye Yabing Cao Zhiming Li Jiajia Huang He Huang Muyan Cai Rongzhen Luo Tongyu Lin Outcome of R-CHOP or CHOP Regimen for Germinal Center and Nongerminal Center Subtypes of Diffuse Large B-Cell Lymphoma of Chinese Patients The Scientific World Journal |
| title | Outcome of R-CHOP or CHOP Regimen for Germinal Center and Nongerminal Center Subtypes of Diffuse Large B-Cell Lymphoma of Chinese Patients |
| title_full | Outcome of R-CHOP or CHOP Regimen for Germinal Center and Nongerminal Center Subtypes of Diffuse Large B-Cell Lymphoma of Chinese Patients |
| title_fullStr | Outcome of R-CHOP or CHOP Regimen for Germinal Center and Nongerminal Center Subtypes of Diffuse Large B-Cell Lymphoma of Chinese Patients |
| title_full_unstemmed | Outcome of R-CHOP or CHOP Regimen for Germinal Center and Nongerminal Center Subtypes of Diffuse Large B-Cell Lymphoma of Chinese Patients |
| title_short | Outcome of R-CHOP or CHOP Regimen for Germinal Center and Nongerminal Center Subtypes of Diffuse Large B-Cell Lymphoma of Chinese Patients |
| title_sort | outcome of r chop or chop regimen for germinal center and nongerminal center subtypes of diffuse large b cell lymphoma of chinese patients |
| url | http://dx.doi.org/10.1100/2012/897178 |
| work_keys_str_mv | AT yinghuang outcomeofrchoporchopregimenforgerminalcenterandnongerminalcentersubtypesofdiffuselargebcelllymphomaofchinesepatients AT shengye outcomeofrchoporchopregimenforgerminalcenterandnongerminalcentersubtypesofdiffuselargebcelllymphomaofchinesepatients AT yabingcao outcomeofrchoporchopregimenforgerminalcenterandnongerminalcentersubtypesofdiffuselargebcelllymphomaofchinesepatients AT zhimingli outcomeofrchoporchopregimenforgerminalcenterandnongerminalcentersubtypesofdiffuselargebcelllymphomaofchinesepatients AT jiajiahuang outcomeofrchoporchopregimenforgerminalcenterandnongerminalcentersubtypesofdiffuselargebcelllymphomaofchinesepatients AT hehuang outcomeofrchoporchopregimenforgerminalcenterandnongerminalcentersubtypesofdiffuselargebcelllymphomaofchinesepatients AT muyancai outcomeofrchoporchopregimenforgerminalcenterandnongerminalcentersubtypesofdiffuselargebcelllymphomaofchinesepatients AT rongzhenluo outcomeofrchoporchopregimenforgerminalcenterandnongerminalcentersubtypesofdiffuselargebcelllymphomaofchinesepatients AT tongyulin outcomeofrchoporchopregimenforgerminalcenterandnongerminalcentersubtypesofdiffuselargebcelllymphomaofchinesepatients |